Pulmonary embolism (PE) is a serious and potentially life-threatening medical condition that affects many people around the world. It is caused when a blood clot travels to the lungs, blocking the flow of oxygenated blood and resulting in potentially fatal complications. PE is also known as the “silent killer” because it often has no warning signs or symptoms and can be difficult to diagnose. It is important for doctors to understand the risk factors associated with PE and to be able to recognize the signs and symptoms in order to provide timely and effective treatment.
Pulmonary embolism is a medical emergency that occurs when a blockage, usually a blood clot, travels from one part of the body to the lungs. The blockage, called an embolus, can be caused by a variety of factors, including deep vein thrombosis (DVT), which is a clot in the veins of the leg. The embolus lodges in the pulmonary arteries, blocking the flow of oxygenated blood to the lungs. This can cause a variety of serious complications, including difficulty breathing, chest pain, and even death.
There are several risk factors that can increase the likelihood of developing pulmonary embolism. These include: • Age: People over the age of 60 are more likely to develop PE than younger individuals. • Gender: Women are more likely to develop PE than men. • Obesity: People who are overweight or obese are at a higher risk for developing PE. • Smoking: Smoking increases the risk of developing PE. • Inactivity: People who are sedentary or who have a history of long periods of inactivity are at a higher risk for developing PE. • Family history: People with a family history of blood clots or PE are more likely to develop PE. • Surgery: People who have recently had surgery, especially major surgery, are at an increased risk of developing PE. • Pregnancy: Pregnant women are more likely to develop PE due to changes in blood flow and clotting factors.
The signs and symptoms of PE can vary from person to person and can range from mild to severe. Some of the most common symptoms include: • Shortness of breath • Chest pain • Coughing • Sweating • Rapid heart rate • Lightheadedness • Fainting It is important to note that some people may not experience any symptoms at all, making PE even more difficult to diagnose.
In order to diagnose PE, doctors will typically use a combination of tests, including a physical exam, chest X-ray, CT scan, echocardiogram, and blood tests. Treatment for PE usually involves the use of anticoagulant medications to help prevent the formation of new clots and to reduce the risk of further complications. In some cases, surgery may be required to remove the clot from the lungs.
Pulmonary embolism is a serious and potentially life-threatening medical condition that affects many people around the world. It is important for doctors to be aware of the risk factors associated with PE and to be able to recognize the signs and symptoms in order to provide timely and effective treatment. With early diagnosis and treatment, the risk of serious complications and death can be greatly reduced.
1.
Preventable pediatric cancer mortality surges in areas of armed conflict, exceeding rates in non-conflict regions
2.
Should the UK introduce targeted prostate cancer screening? The case for and against
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
A healthier lifestyle after bowel screening shown to prevent bowel cancer
5.
A better option for mild to moderate depression?
1.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
2.
The Unseen Danger of Anal Cancer: How to Protect Yourself
3.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
4.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
5.
Unlocking the Mystery of Elliptocytes: Exploring the Unusual Shape of Red Blood Cells
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation